Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
ARA-290 vs Thymalin
An educational, source-based comparison of ARA-290 and Thymalin — how each peptide works, what it's researched for, and what to know before going deeper.
Erythropoietin-derived peptide researched for neuropathy and tissue repair.
A synthetic 11-amino-acid peptide derived from the erythropoietin molecule. Research indicates it retains the tissue-protective (non-erythropoietic) effects of EPO via the β-common receptor, without stimulating red blood cell production.
- Small-fiber neuropathy and sarcoidosis
- Diabetic neuropathy
- Ischemia-reperfusion injury
- Autoimmune modulation
- • Investigational; not FDA-approved.
- • Does not raise hematocrit like full EPO molecule.
A polypeptide complex extracted from calf thymus, studied as an immune bioregulator. Research suggests restoration of T-cell function and thymic activity in aged and immunocompromised cohorts.
- Immunosenescence
- Recovery from infection in elderly cohorts
- Adjunct in chronic inflammatory conditions
- • Approved in Russia; not FDA-approved.
- • Mixture composition is not fully characterized.
ARA-290 vs Thymalin — Key differences
- Class: ARA-290 is classified as Neuropathic · Immune Modulation, while Thymalin is Immune · Bioregulator.
- Primary research focus: ARA-290 — small-fiber neuropathy and sarcoidosis; Thymalin — immunosenescence.
- Tag: Neuropathic pain · Immune vs Immune · Longevity.